STAR-0602

DelveInsight's latest report reveals a robust pipeline with over 195 companies developing 200+ therapies for colorectal cancer, highlighting significant innovation in targeted treatments and immunotherapies.

The FDA granted Fast Track designation to invikafusp alfa (STAR0602) for advanced colorectal cancer with high tumor mutational burden (TMB-H).

Marengo Therapeutics has dosed the first patient in its European expansion of the invikafusp alfa trial, marking a significant step in oncology research. This development is part of a broader trend in first-in-human (FIH) clinical trials, with oncology leading as the largest therapy area.

Marengo Therapeutics has dosed the first patient in the Phase 2 portion of the STARt-001 trial, evaluating invikafusp alfa in advanced anti-PD-1 resistant solid tumors.

Invikafusp alfa demonstrated a 50% disease control rate in heavily pretreated patients with anti–PD-(L)1–resistant solid tumors in the phase 1/2 STARt-001 trial.